Review
Version 1
Preserved in Portico This version is not peer-reviewed
An Update on Pharmacotherapy of Glaucoma
and
*
Version 1
: Received: 29 July 2023 / Approved: 31 July 2023 / Online: 31 July 2023 (10:26:59 CEST)
How to cite: Virani, S.; Rewri, P. An Update on Pharmacotherapy of Glaucoma. Preprints 2023, 2023072095. https://doi.org/10.20944/preprints202307.2095.v1 Virani, S.; Rewri, P. An Update on Pharmacotherapy of Glaucoma. Preprints 2023, 2023072095. https://doi.org/10.20944/preprints202307.2095.v1
Abstract
Progressive loss of retinal ganglionic cells (RGC) causes blindness in glaucoma. Elevated intraocular pressure (IOP) is the most important, treatable risk factor. Currently, the management of glaucoma is centred at reducing the IOP, and drugs in the form of topical drops are the first line of management. Drugs reduce IOP either by suppressing aqueous humour secretion or improving the aqueous humour outflow. Newer drugs added during the past three decades to the armamentarium of glaucoma treatment have targeted the aqueous outflow. With an evolving understanding of the pathogenesis of glaucoma, the role of 24-hour IOP control and other IOP-independent risk factors affecting ocular blood flow and RGC toxicity is also recognised. The role of available drugs in controlling IOP over 24-hours is being evaluated. Improvement of ocular blood flow and neuroprotection are seen as potential drug targets in preventing the loss of RGC. In this article, we review the pharmacotherapy of glaucoma based on current therapeutic principles.
Keywords
glaucoma; pharmacotherapy; intraocular pressure; 24-hour IOP control; neuroprotection; adjuvent therapy; ocular blood flow
Subject
Medicine and Pharmacology, Ophthalmology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
